AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27763846 — intervention group
Group type: EXPERIMENTAL
Intervention: Infographic format
Number of subjects: 2008
Study 27763846 — intervention group
Group type: EXPERIMENTAL
Intervention: Large font calorie condition
Number of subjects: 2008
Study 25496425 — intervention group
Group type: EXPERIMENTAL
Intervention: Dementia-specific case conferences
Number of subjects: 0
Study 25496425 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 23336412 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein-free calf blood extract ophthalmic gel
Number of subjects: 36
Study 23336412 — intervention group
Group type: COMPARATOR
Intervention: Recombinant bovine basic fibroblast growth factor ophthalmic gel
Number of subjects: 36
Study 20198491 — intervention group
Group type: EXPERIMENTAL
Intervention: Gatekeeper Reflux Repair System (GK)
Number of subjects: 204
Study 20198491 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 204
Study 19063816 — intervention group
Group type: EXPERIMENTAL
Intervention: Olopatadine 0.2% ophthalmic solution
Number of subjects: 60
Study 19063816 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone furoate nasal spray
Number of subjects: 60
Study 12764120 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal suggestions of analgesia/hyperalgesia
Number of subjects: 0
Study 12764120 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal suggestions of motor improvement/worsening
Number of subjects: 0
Study 12764120 — intervention group
Group type: EXPERIMENTAL
Intervention: Preconditioning with sumatriptan (5‐HT(1B/1D) agonist) followed by placebo administration
Number of subjects: 0
Study 12764120 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal suggestions of increase/decrease of growth hormone (GH) and cortisol
Number of subjects: 0
Study 10696854 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal challenge with NRL
Number of subjects: 31
Study 10696854 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 9327315 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam + Oral Transmucosal Fentanyl Citrate (OTFC)
Number of subjects: 0
Study 9327315 — intervention group
Group type: COMPARATOR
Intervention: Midazolam + Placebo
Number of subjects: 0
Study 8447743 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Number of subjects: 256
Study 3769604 — intervention group
Group type: EXPERIMENTAL
Intervention: Day-care program designed to prevent mild mental retardation
Number of subjects: 80
Study 3769604 — intervention group
Group type: COMPARATOR
Intervention: Educationally untreated control group
Number of subjects: 80
Study 30982086 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT)
Number of subjects: 38
Study 30982086 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 38
Study 29456128 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS combined with CIMT
Number of subjects: 20
Study 29456128 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS combined with CIMT
Number of subjects: 20
Study 29456128 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with preserved corticospinal tract circuitry
Number of subjects: 20
Study 26968024 — intervention group
Group type: EXPERIMENTAL
Intervention: Early goal‐directed mobilization
Number of subjects: 50
Study 26968024 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 50
Study 25156854 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-electrode, phased radiofrequency ablation (MER group)
Number of subjects: 460
Study 25156854 — intervention group
Group type: COMPARATOR
Intervention: Conventional, point‐by‐point ablation with a radiofrequency ablation catheter (cPVI group)
Number of subjects: 460
Study 25156854 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (cPVI and MER)
Number of subjects: 460
Study 22423099 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticomuscular coherence during articulation
Number of subjects: 0
Study 22423099 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticomuscular coherence
Number of subjects: 0
Study 19955098 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative diarrhoea occurrence over 14 days
Number of subjects: 0
Study 19955098 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative diarrhoea occurrence over 28 days
Number of subjects: 0
Study 19955098 — intervention group
Group type: COMPARATOR
Intervention: Trial arms comparison
Number of subjects: 0
Study 18157519 — intervention group
Group type: EXPERIMENTAL
Intervention: UDCA (300 mg/day)
Number of subjects: 14
Study 18157519 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 15753414 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate (2.5 mg daily for 12 months)
Number of subjects: 374
Study 15753414 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 374
Study 12616667 — intervention group
Group type: EXPERIMENTAL
Intervention: Nizatidine in apple juice
Number of subjects: 24
Study 12616667 — intervention group
Group type: EXPERIMENTAL
Intervention: Nizatidine in infant formula
Number of subjects: 24
Study 12616667 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercially prepared oral syrup
Number of subjects: 24
Study 12616667 — intervention group
Group type: COMPARATOR
Intervention: Reference capsule formulation
Number of subjects: 24
Study 10546521 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen and/or chemotherapy
Number of subjects: 0
Study 10546521 — intervention group
Group type: EXPERIMENTAL
Intervention: New cytotoxic drugs (taxanes, vinorelbine, capecitabine), high dose chemotherapy, immunotherapy with monoclonal antibodies (herceptin), gene therapeutic approaches
Number of subjects: 0
Study 10546521 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive factors and biological markers
Number of subjects: 0
Study 8699547 — intervention group
Group type: EXPERIMENTAL
Intervention: Compulsory supervision group
Number of subjects: 610
Study 8699547 — intervention group
Group type: COMPARATOR
Intervention: Voluntary group (no compulsory supervision)
Number of subjects: 610
Study 2061529 — intervention group
Group type: EXPERIMENTAL
Intervention: Planned walking for 30 minutes three times a week for 10 weeks
Number of subjects: 30
Study 2061529 — intervention group
Group type: COMPARATOR
Intervention: Conversation for 30 minutes three times a week for 10 weeks
Number of subjects: 30
Study 6406616 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin prophylaxis (5 doses of 1g)
Number of subjects: 361
Study 6406616 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 361
Study 6406616 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin prophylaxis
Number of subjects: 361
Study 29737412 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate
Number of subjects: 1261
Study 27522486 — intervention group
Group type: EXPERIMENTAL
Intervention: Speedinc (baseline pump speed + 800 rpm)
Number of subjects: 19
Study 27522486 — intervention group
Group type: COMPARATOR
Intervention: Speedbase (fixed baseline pump speed)
Number of subjects: 19
Study 26761562 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive video-game group intervention
Number of subjects: 39
Study 26761562 — intervention group
Group type: COMPARATOR
Intervention: Traditional group intervention
Number of subjects: 39
Study 24333554 — intervention group
Group type: EXPERIMENTAL
Intervention: Rg3-loaded PLGA electrospun fibrous membranes
Number of subjects: 0
Study 24333554 — intervention group
Group type: COMPARATOR
Intervention: Control groups (not specified)
Number of subjects: 0
Study 23091128 — intervention group
Group type: COMPARATOR
Intervention: Group F: heat‐inactivated Lactobacillus salivarius and Bacillus subtilis
Number of subjects: 1800
Study 23091128 — intervention group
Group type: COMPARATOR
Intervention: Group G: inactivated Lactobacillus salivarius and sodium butyrate
Number of subjects: 1800
Study 23091128 — intervention group
Group type: COMPARATOR
Intervention: Groups D and H
Number of subjects: 1800
Study 23091128 — intervention group
Group type: COMPARATOR
Intervention: Groups B, H, and I
Number of subjects: 1800
Study 23091128 — intervention group
Group type: COMPARATOR
Intervention: Groups D, E, and G
Number of subjects: 1800
Study 23091128 — intervention group
Group type: COMPARATOR
Intervention: Groups E and G
Number of subjects: 1800
Study 23091128 — intervention group
Group type: COMPARATOR
Intervention: Groups B, C, E, G, and I after d 15
Number of subjects: 1800
Study 23091128 — intervention group
Group type: COMPARATOR
Intervention: Groups B, C, D, E, F, G, and H after d 45
Number of subjects: 1800
Study 23091128 — intervention group
Group type: COMPARATOR
Intervention: Groups F and G at d 45
Number of subjects: 1800
Study 19114683 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab plus FOLFOX‐4 (n = 169)
Number of subjects: 337
Study 19114683 — intervention group
Group type: COMPARATOR
Intervention: FOLFOX‐4 alone (n = 168)
Number of subjects: 337
Study 19114683 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab plus FOLFOX‐4 in KRAS wild-type tumors
Number of subjects: 337
Study 19114683 — intervention group
Group type: COMPARATOR
Intervention: FOLFOX‐4 alone in KRAS wild-type tumors
Number of subjects: 337
Study 17968180 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloprost in saline solution for 3 weeks
Number of subjects: 98
Study 17968180 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (control)
Number of subjects: 98
Study 14767293 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral modification program (BMP)
Number of subjects: 359
Study 14767293 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 359
Study 11719297 — intervention group
Group type: EXPERIMENTAL
Intervention: Proportional Assist Ventilation (PAV)
Number of subjects: 44
Study 11719297 — intervention group
Group type: COMPARATOR
Intervention: Pressure Support Ventilation (PSV)
Number of subjects: 44
Study 9425969 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia with 3.4 mL of hypobaric 0.18% bupivacaine (6.12 mg)
Number of subjects: 70
Study 8483561 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin (100 mg/m2)
Number of subjects: 60
Study 8483561 — intervention group
Group type: COMPARATOR
Intervention: FEM (5-fluorouracil 600 mg/m2, epirubicin 50 mg/m2, mitomycin 6 mg/m2)
Number of subjects: 60
Study 2961394 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulation
Number of subjects: 0
Study 2961394 — intervention group
Group type: EXPERIMENTAL
Intervention: Traction
Number of subjects: 0
Study 2961394 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural injections
Number of subjects: 0
Study 2961394 — intervention group
Group type: EXPERIMENTAL
Intervention: Sclerosants
Number of subjects: 0
Study 30545409 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive external facilitation implementation intervention to increase OAT prescribing rates
Number of subjects: 8
Study 30545409 — intervention group
Group type: COMPARATOR
Intervention: Control sites (not specified in detail)
Number of subjects: 8
Study 26791805 — intervention group
Group type: EXPERIMENTAL
Intervention: Testofen (Trigonella foenum-graecum seed extract) at a dose of 600 mg/day for 12 weeks
Number of subjects: 120
Study 26791805 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 24257810 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 20
Study 24257810 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 23216401 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term individual dynamic therapy
Number of subjects: 100
Study 23216401 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant medication (augmented treatment)
Number of subjects: 100
Study 20507973 — intervention group
Group type: EXPERIMENTAL
Intervention: Aged group at rest
Number of subjects: 12
Study 20507973 — intervention group
Group type: EXPERIMENTAL
Intervention: Aged group during exercise
Number of subjects: 12
Study 18179314 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurofeedback-induced decrease in relative left frontal cortical activation
Number of subjects: 0
Study 18179314 — intervention group
Group type: EXPERIMENTAL
Intervention: Action-oriented mindset manipulation
Number of subjects: 0
Study 15933528 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin sealant (Tisseel) added to tonsillar fossa during tonsillectomy
Number of subjects: 40
Study 15933528 — intervention group
Group type: COMPARATOR
Intervention: Traditional complete tonsillectomy without fibrin sealant
Number of subjects: 40
Study 12589986 — intervention group
Group type: EXPERIMENTAL
Intervention: CPR plus use of an AED
Number of subjects: 1000
Study 12589986 — intervention group
Group type: COMPARATOR
Intervention: CPR alone
Number of subjects: 1000
Study 12814316 — intervention group
Group type: EXPERIMENTAL
Intervention: HA-coated threaded implants
Number of subjects: 120
Study 12814316 — intervention group
Group type: EXPERIMENTAL
Intervention: HA-coated cylindric implants
Number of subjects: 120
Study 12814316 — intervention group
Group type: EXPERIMENTAL
Intervention: machined Ti threaded implants
Number of subjects: 120
Study 9780560 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiandrogen therapy combined with radiation therapy
Number of subjects: 0
Study 9780560 — intervention group
Group type: COMPARATOR
Intervention: Radiation therapy alone
Number of subjects: 0
Study 7624193 — intervention group
Group type: EXPERIMENTAL
Intervention: Inconsistent picture
Number of subjects: 0
Study 7624193 — intervention group
Group type: COMPARATOR
Intervention: Consistent picture
Number of subjects: 0
Study 2529333 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-directed oocyte pickup (OPU)
Number of subjects: 94
Study 2529333 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic oocyte pickup (OPU)
Number of subjects: 94
Study 16622 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlordesmethyldiazepam
Number of subjects: 20
Study 16622 — intervention group
Group type: COMPARATOR
Intervention: Lorazepam
Number of subjects: 20
Study 31843827 — intervention group
Group type: EXPERIMENTAL
Intervention: Health insurance coverage (at least one member covered)
Number of subjects: 300
Study 31843827 — intervention group
Group type: COMPARATOR
Intervention: Unemployment
Number of subjects: 300
Study 31843827 — intervention group
Group type: COMPARATOR
Intervention: Seeking care from a public health facility
Number of subjects: 300
Study 31843827 — intervention group
Group type: COMPARATOR
Intervention: Perceived health status as good
Number of subjects: 300
Study 31843827 — intervention group
Group type: COMPARATOR
Intervention: Unsatisfied with the cost of seeking primary care
Number of subjects: 300
Study 28170391 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dose of primaquine (1 mg base/kg/day for 7 days)
Number of subjects: 241
Study 28170391 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard high dose of primaquine (0.5 mg base/kg/day for 14 days)
Number of subjects: 241
Study 26432125 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial coherence interferometry (PCI) measurements with ACMaster device
Number of subjects: 65
Study 26432125 — intervention group
Group type: EXPERIMENTAL
Intervention: Optical low-coherence reflectometry (OLCR) measurements with Lenstar LS900 device
Number of subjects: 65
Study 26432125 — intervention group
Group type: COMPARATOR
Intervention: Comparison of PCI and OLCR measurements
Number of subjects: 65
Study 23859649 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher endogenous testosterone levels in boys
Number of subjects: 268
Study 23859649 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher endogenous testosterone levels in girls
Number of subjects: 268
Study 23859649 — intervention group
Group type: EXPERIMENTAL
Intervention: Smaller medial OFC volume in boys
Number of subjects: 268
Study 23859649 — intervention group
Group type: EXPERIMENTAL
Intervention: Larger OFC surface area in girls
Number of subjects: 268
Study 23859649 — intervention group
Group type: EXPERIMENTAL
Intervention: OFC morphology
Number of subjects: 268
Study 21616170 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 g of milled flaxseed per day
Number of subjects: 110
Study 21616170 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 19230757 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral iron therapy
Number of subjects: 0
Study 19230757 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16765760 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat intramuscular dose of 11.4 mg betamethasone (as Celestone Chronodose)
Number of subjects: 982
Study 16765760 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 982
Study 14757602 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized epinephrine (0.9 mg/kg of 2.25% racemic epinephrine)
Number of subjects: 66
Study 14757602 — intervention group
Group type: COMPARATOR
Intervention: Nebulized albuterol (0.15 mg/kg of 0.5% albuterol sulfate)
Number of subjects: 66
Study 14757602 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized epinephrine
Number of subjects: 66
Study 14757602 — intervention group
Group type: COMPARATOR
Intervention: Nebulized albuterol
Number of subjects: 66
Study 14757602 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 66
Study 11710391 — intervention group
Group type: EXPERIMENTAL
Intervention: LBNP group, received -4.0 kPa LBNP training 1 h/d in the last week of the test
Number of subjects: 12
Study 11710391 — intervention group
Group type: COMPARATOR
Intervention: Control group, exposed to -6 degrees HDT for 21 days without LBNP training
Number of subjects: 12
Study 11710391 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (LBNP and Control) during HDT
Number of subjects: 12
Study 11710391 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (LBNP and Control) post HDT
Number of subjects: 12
Study 9437950 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron
Number of subjects: 101
Study 9437950 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide
Number of subjects: 101
Study 9437950 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study 8497648 — intervention group
Group type: EXPERIMENTAL
Intervention: Tangential fluoroscopic guidance (group A)
Number of subjects: 92
Study 8497648 — intervention group
Group type: COMPARATOR
Intervention: No tangential fluoroscopic guidance (group B)
Number of subjects: 92
Study 2963230 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose leucovorin plus FUra (Arm B)
Number of subjects: 102
Study 2963230 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential methotrexate, FUra, leucovorin (Arm C)
Number of subjects: 102
Study 31314564 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT group intervention
Number of subjects: 71
Study 31314564 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 71
Study 28049559 — intervention group
Group type: EXPERIMENTAL
Intervention: Image-interpretive task workflow
Number of subjects: 1
Study 28049559 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-image interpretive task workflow
Number of subjects: 1
Study 28049559 — intervention group
Group type: EXPERIMENTAL
Intervention: Image interpretation
Number of subjects: 1
Study 28049559 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-image interpretive tasks (phone calls/paging)
Number of subjects: 1
Study 28049559 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-image interpretive tasks (in-room consultations)
Number of subjects: 1
Study 28049559 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-image interpretive tasks (protocoling)
Number of subjects: 1
Study 28049559 — intervention group
Group type: EXPERIMENTAL
Intervention: Consult assistant (CA)
Number of subjects: 1
Study 25830947 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus paracasei ssp. paracasei F19 (LF19) 10(8) CFU
Number of subjects: 179
Study 25830947 — intervention group
Group type: COMPARATOR
Intervention: Placebo (cereals without LF19)
Number of subjects: 179
Study 22820873 — intervention group
Group type: EXPERIMENTAL
Intervention: Tuning into Kids (TIK) parenting program
Number of subjects: 54
Study 22820873 — intervention group
Group type: COMPARATOR
Intervention: Waitlist (clinical treatment as usual)
Number of subjects: 54
Study 21853859 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid-carbohydrate (AACHO) prior to resistance exercise (979 kJ, 36 g carbohydrate, 22.5 g protein)
Number of subjects: 6
Study 21853859 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLAC) prior to resistance exercise
Number of subjects: 6
Study 21853859 — intervention group
Group type: EXPERIMENTAL
Intervention: AACHO and PLAC (pooled)
Number of subjects: 6
Study 18820657 — intervention group
Group type: EXPERIMENTAL
Intervention: Subconjunctival injection of 20 mg triamcinolone acetonide with topical 1% prednisolone acetate
Number of subjects: 32
Study 18820657 — intervention group
Group type: COMPARATOR
Intervention: Intravenous injection of 500 mg methylprednisolone with topical 1% prednisolone acetate
Number of subjects: 32
Study 17302057 — intervention group
Group type: EXPERIMENTAL
Intervention: Xuefu Zhuyu Decoction (XZD)
Number of subjects: 123
Study 17302057 — intervention group
Group type: EXPERIMENTAL
Intervention: Refined Xuefu Zhuyu Decoction
Number of subjects: 123
Study 17302057 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-pair group
Number of subjects: 123
Study 17302057 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 123
Study 15118485 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg Delta-9-tetrahydrocannabinol (THC)
Number of subjects: 8
Study 15118485 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg THC combined with 5 mg cannabidiol (CBD)
Number of subjects: 8
Study 15118485 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg THC combined with 15 mg CBD
Number of subjects: 8
Study 15118485 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 11487601 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive task (dual-task paradigm)
Number of subjects: 28
Study 11487601 — intervention group
Group type: COMPARATOR
Intervention: Single task (no cognitive task)
Number of subjects: 28
Study 9542820 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment (beta-adrenoceptor blockers and/or thiazide diuretics)
Number of subjects: 686